Clinicopathologic characteristics and survival in BRCA1- and BRCA2-related adnexal cancer: Are they different?

International Journal of Gynecological Cancer

Volumn 22, Issue 4, 2012, Pages 579-585

  Reitsma, Welmoed ^a   De Bock, Geertruida H ^b   Oosterwijk, Jan C ^b   Ten Hoor, Klaske A ^a   Hollema, Harry ^b   Mourits, Marian J E ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

BRCA; Clinicopathologic features; Ovarian cancer; Survival; Tumor characteristics

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; PACLITAXEL; PLATINUM DERIVATIVE;

ADNEXAL CANCER; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RELAPSE; CANCER RESISTANCE; CANCER SURVIVAL; CANCER THERAPY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC COUNSELING; GYNECOLOGIC CANCER; GYNECOLOGICAL EXAMINATION; HETEROZYGOTE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; MUTATIONAL ANALYSIS; OVARY CANCER; OVERALL SURVIVAL; PERITONEUM CANCER; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RISK ASSESSMENT; TUBAL CANCER; TUMOR LOCALIZATION;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; BRCA1 PROTEIN; BRCA2 PROTEIN; COHORT STUDIES; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FALLOPIAN TUBE NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROGNOSIS; SURVIVAL RATE;

EID: 84863699445     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31823d1b5c     Document Type: Article

References (24)

1. Claus EB, Schildkraut JM, Thompson WD, et al. The genetic attributable risk of breast and ovarian cancer. Cancer. 1996;77:2318-2324.
2. Zhang S, Royer R, Li S, et al. Frequencies of BRCA1 and BRCA2 mutations among 1, 342 unselected patients with invasive ovarian cancer. Gynecol Oncol. 2011;121:353-357.
3. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117-1130.
4. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25:1329-1333.
5. Aziz S, Kuperstein G, Rosen B, et al. A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol. 2001;80:341-345.
6. Cass I, Holschneider C, Datta N, et al. BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype? Obstet Gynecol. 2005;106:1327-1334.
7. Boyd J, Sonoda Y, Federici MG, et al. Clinicopathologic features of BRCA-associated and sporadic ovarian cancer. JAMA. 2000;283:2260-2265.
8. Cass I, Baldwin RL, Varkey T, et al. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer. 2003;97:2187-2195.
9. Vencken PM, Kriege M, Hoogwerf D, et al. Chemosensitivity and outcome of BRCA1-and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients. Ann Oncol. 2011;22:1346-1352.
10. Rijnsburger AJ, Obdeijn IM, Kaas R, et al. BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study. J Clin Oncol. 2010;28:5265-5273.
11. Woolas R, Smith J, Saharnis P, et al. Fallopian tube carcinoma: an under-recognized primary neoplasm. Int J Gynecol Cancer. 1997;7:284-288.
12. Werness BA, Ramus SJ, DiCioccio RA, et al. Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry. Int J Gynecol Pathol. 2004;23:29-34.
13. Piek JM, Torrenga B, Hermsen B, et al. Histopathological characteristics of BRCA1-and BRCA2-associated intraperitoneal cancer: a clinic-based study. Fam Cancer. 2003;2:73-78.
14. Jarboe EA, Folkins AK, Drapkin R, et al. Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. Histopathology. 2008;53:127-138.
15. Finch A, Shaw P, Rosen B, et al. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol. 2006;100:58-64.
16. Callahan MJ, Crum CP, Medeiros F, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol. 2007;25:3985-3990.
17. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346:1616-1622.
18. Casey MJ, Synder C, Bewtra C, et al. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Gynecol Oncol. 2005;97:457-467.
19. Seidman JD, Zhao P, Yemelyanova A. "Primary peritoneal" high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer. Gynecol Oncol. 2011;120:470-473.
20. Olivier RI, Lubsen-Brandsma LA, van Boven H, et al. Additional salpingectomy after previous prophylactic oophorectomy in high-risk women: sense or nonsense? Gynecol Oncol. 2005;96:439-443.
21. Lakhani SR, Manek S, Penault-Llorca F, et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res. 2004;10:2473-2481.
22. Byrd LM, Shenton A, Maher ER, et al. Better life expectancy in women with BRCA2 compared with BRCA1 mutations is attributable to lower frequency and later onset of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2008;17:1535-1542.
23. Pharoah PD, Easton DF, Stockton DL, et al. Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. Cancer Res. 1999;59:868-871.
24. Board RE, Bruijns CT, Pronk AE, et al. Stage-and CA125-related survival in patients with epithelial ovarian cancer treated at a cancer center. Int J Gynecol Cancer. 2006;16(suppl 1):18-24.